ArticleScientific reports2025
Independent effects of Metformin and Dapagliflozin on Fetuin-A, hepatic and pancreatic fat, and hepatic fibrosis in Asian Indians with type 2 diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic implications of hepatic, pancreatic and abdominal adipose tissue depots in Asian Indians across normoglycaemia, prediabetes and type 2 diabetes.Diabetologia · 2026Article
- Key Hepatokines Linking MASLD and Type 2 Diabetes: From Pathophysiological Mechanisms to Therapeutic Modulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously we have reported decrease in hepatic and pancreatic fat fraction with Dapagliflozin (DAPA). In this research, we evaluated the effects of Metformin intervention for 120 days on hepatic fat fraction (HFF) and pancreatic fat fraction (PFF), hepatic fibrosis, and Metformin and DAPA, on Fetuin-A levels in patients with type 2 diabetes (T2D). Patients were given 1000 mg of Metformin/day (n, 15) and DAPA 10 mg/day (n, 30) for a period of 120 days. Changes in anthropometry, surrogate markers of insulin resistance, body composition, vibration-controlled transient elastography (VTE, for CAP, and kPa) parameters, HFF) and PFF (both by MRI-PDFF) and serum fetuin-A levels were evaluated. After 120 days of treatment with Metformin and DAPA, a significant reduction in body weight, body mass index (BMI), percentage body fat, waist and hip circumferences, and total skinfold thickness was observed. A significant reduction in fetuin-A was seen with both Metformin and DAPA treatment, previously not reported for latter drug. Metformin significantly decreased CAP and kPa (VTE) but did not decrease HFF and PFF. Metformin and DAPA, after 120 days of use, reduced Fetuin-A levels, and Metformin decreased CAP and kPa but not HFF and PFF. Reduction of Fetuin-A levels with Metformin and DAPA have important pathophysiological implications for T2D in Asian Indians.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.